More recently, the coadministration of CD19- and CD22-targeting CAR T-cells was a novel approach adopted by Wand and colleagues in a phase II trial in patients aged ≤ 20 years with R/R B-ALL. Here, CD22 is linked to acute lymphoblastic leukemia.